Efforts to address the health-related social needs (HRSN) of Medicare and Medicaid beneficiaries, such as housing and food, during the COVID-19 pandemic were insufficient.
Rystiggo receives FDA approval, strengthening UCB’s myasthenia gravis portfolio – Pharmaceutical Technology
Generalised myasthenia gravis is a rare condition – but UCB’s Rystiggo enters a competitive market. Source: Shutterstock / Giovanni Cancemi. Belgian biopharmaceutical company UCB has